rolipram has been researched along with Cardiomyopathies, Primary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, J | 1 |
| Liu, Z | 2 |
| Hong, X | 1 |
| Gao, J | 1 |
| Liu, J | 1 |
| Mohamed, HE | 1 |
| Asker, ME | 1 |
| Ali, SI | 1 |
| el-Fattah, TM | 1 |
2 other studies available for rolipram and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Protective effects of rolipram on endotoxic cardiac dysfunction via inhibition of the inflammatory response in cardiac fibroblasts.
Topics: Animals; Anti-Inflammatory Agents; Cardiomyopathies; Cells, Cultured; Cytokines; Disease Models, Ani | 2020 |
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopa | 2004 |